Najjar, Y. G., Robert, C., Khushalani, N. I., Wong, M. K., Bowles, T. L., Ascierto, P. A., Long, G. V., Schadendorf, D., Betof, A., Daniels, G. A., In, G. K., Collichio, F. A., Davarifar, A., Saenger, Y. M., Rapisuwon, S., Weight, R. M., Gullo, G., Viana, M., Navarro, M., Hamid, O. (2026). A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps9597